EMCDDA Home
  • EN
Search

Data: statistical bulletin 2012

The interactive version of the Statistical bulletin should appear in your browser window in a matter of seconds. If, however, you continue to see either this text and/or a loading status message, the interactive version may not be functioning correctly. This could be due to your browser's settings, the version of browser you're using, or a technical error on our side. Please begin by consulting the Explanatory notes and help page but feel free to contact us for further assistance (online[a]emcdda.europa.eu — dont't forget to replace '[a]' with '@' before sending the message).

Please note you can also access all statistical elements and data on the listing of all statistics page.

About the Statistical bulletin

The Statistical bulletin is published yearly by the EMCDDA and provides access to the most recent statistical data relating to the drugs situation in Europe. Statistics are organised by category. In addition to the statistical tables and graphs, an overview of the data is provided for each category.

Data: statistical bulletin 2012

The Statistical bulletin is published yearly by the EMCDDA and consists of over 400 tables and 100 graphs of the most recent available data on the drug situation in Europe, all available to view interactively on screen and download in Excel format.

The information covers a broad range of areas including the most recent estimates of treatment and prevalence, information on focused studies of drug related infectious diseases and of problem drug use, levels of drug related deaths, drug related crime in the form of drug seizures, types of offence, price, purity and use in prison, and country responses to the drug situation in Europe.

The Statistical bulletin is the result of close interaction between focal points and experts at the country level, and the EMCDDA at the European level. A highlight this year is the inclusion of data from the most recent European School Survey Project on Alcohol and Other Drugs (ESPAD) which provides an important insight into drug use at school level across Europe.

About the data

The information provided here may be freely reused, provided it is reproduced accurately, not presented in a misleading way and that all sources are acknowledged (see the help page for full details).

To get started, select one of the categories below.

Prevalence and population estimates

Infectious diseases and deaths

Treatment demand and health and social responses

Crime, seizures and market data

Type Category Prefix Number Part Title Part title Alias Reference File name
Table DLO dlotab1 1 i Drug law offences, 1995 to 2010 Number of reports of offences /stats12/dlotab1a dlotab1a Table-DLO-01-parti.xml
Table DLO dlotab1 1 ii Drug law offences, 1995 to 2010 Number of reports of persons /stats12/dlotab1b dlotab1b Table-DLO-01-partii.xml
Table DLO dlotab1 1 iii Drug law offences, 1995 to 2010 Methodological notes /stats12/dlotab1c dlotab1c Table-DLO-01-partiii.xml
Table DLO dlotab2 2 i Offence types in reports for drug law offences, 2009 or 2010 Number and percentage of all reports for drug law offences /stats12/dlotab2a dlotab2a Table-DLO-02-parti.xml
Table DLO dlotab2 2 ii Offence types involved in reports for drug law offences: methods of percentages calculation for drug law offences Methodological notes /stats12/dlotab2b dlotab2b Table-DLO-02-partii.xml
Table DLO dlotab3 3 i Drug types in reports for drug law offences, 2009 or 2010 Number and percentage of all reports for drug law offences /stats12/dlotab3a dlotab3a Table-DLO-03-parti.xml
Table DLO dlotab3 3 ii Drug types in reports for drug law offences Methodological notes /stats12/dlotab3b dlotab3b Table-DLO-03-partii.xml
Table DLO dlotab4 4 i Drug law offences related to drug use or possession for use, 2003 to 2010 Number and percentage /stats12/dlotab4a dlotab4a Table-DLO-04-parti.xml
Table DLO dlotab4 4 ii Drug law offences related to drug use or possession for use, 2003 to 2010 Methodological notes /stats12/dlotab4b dlotab4b Table-DLO-04-partii.xml
Table DLO dlotab5 5 i Drug law offences related to drug supply, 2003 to 2010 Number and percentage /stats12/dlotab5a dlotab5a Table-DLO-05-parti.xml
Table DLO dlotab5 5 ii Drug law offences related to drug supply, 2003 to 2010 Methodological notes /stats12/dlotab5b dlotab5b Table-DLO-05-partii.xml
Table DLO dlotab6 6 i Cannabis-related offences, 2003 to 2010 Number and percentage of all drug law offences /stats12/dlotab6a dlotab6a Table-DLO-06-parti.xml
Table DLO dlotab6 6 ii Cannabis-related offences, 2003 to 2010 Methodological notes /stats12/dlotab6b dlotab6b Table-DLO-06-partii.xml
Table DLO dlotab7 7 i Heroin-related offences, 2003 to 2010 Number and percentage of all drug law offences /stats12/dlotab7a dlotab7a Table-DLO-07-parti.xml
Table DLO dlotab7 7 ii Heroin-related offences, 2003 to 2010 Methodological notes /stats12/dlotab7b dlotab7b Table-DLO-07-partii.xml
Table DLO dlotab8 8 i Cocaine-related offences, 2003 to 2010 Number and percentage of all drug law offences /stats12/dlotab8a dlotab8a Table-DLO-08-parti.xml
Table DLO dlotab8 8 ii Cocaine-related offences, 2003 to 2010 Methodological notes /stats12/dlotab8b dlotab8b Table-DLO-08-partii.xml
Table DLO dlotab109 109 i Number of reports for drug law offences, 1985 to 2010 Number of reports of offences /stats12/dlotab109a dlotab109a Table-DLO-109-parti.xml
Table DLO dlotab109 109 ii Number of reports for drug law offences, 1985 to 2010 Number of reports of persons /stats12/dlotab109b dlotab109b Table-DLO-109-partii.xml
Table DLO dlotab109 109 iii Number of reports for drug law offences, 1985 to 2010 Methodological notes /stats12/dlotab109c dlotab109c Table-DLO-109-partiii.xml
Figure DLO dlofig1 1   Indexed trends in reports for drug-related offences by broad type of offence in the EU Member States, 2005–10   /stats12/dlofig1 dlofig1 Table-DLO-g01-parti.xml
Figure DLO dlofig2 2   Offence types in reports for drug law offences in the EU Member States, Croatia and Norway, 2009 or 2010   /stats12/dlofig2 dlofig2 Table-DLO-g02-parti.xml
Figure DLO dlofig3 3   Indexed trends in reports for drug law offences by type of drug in the EU Member States, 2005–10   /stats12/dlofig3 dlofig3 Table-DLO-g03-parti.xml
Figure DLO dlofig4 4   Indexed trends in reports for offences related to drug use or possession for use in the EU Member States, 2005–10   /stats12/dlofig4 dlofig4 Table-DLO-g04-parti.xml
Figure DLO dlofig5 5   Indexed trends in reports for offences related to drug supply in the EU Member States, 2005–10   /stats12/dlofig5 dlofig5 Table-DLO-g05-parti.xml
Table DRD drdtab0 0   Drug-induced deaths recorded in EU Member States according to national definitions: sources and bibliographic references   /stats12/drdtab0 drdtab0 Table-DRD-00-part0.xml
Table DRD drdtab1 1 i Summary of characteristics of the deceased in drug-induced deaths according to national definitions Demographic characteristics, 2010 or last year with available information /stats12/drdtab1a drdtab1a Table-DRD-01-parti.xml
Table DRD drdtab1 1 ii Summary of characteristics of the deceased in drug-induced deaths according to national definitions Numbers of drug-induced deaths and toxicology, 2010 or last year with available information /stats12/drdtab1b drdtab1b Table-DRD-01-partii.xml
Table DRD drdtab1 1 iii Summary of characteristics of the deceased in drug-induced deaths according to national definitions Demographic characteristics and toxicology, 1990 or earliest year with available information /stats12/drdtab1c drdtab1c Table-DRD-01-partiii.xml
Table DRD drdtab2 2 i Number of drug-induced deaths recorded in EU Member States according to national definitions Total drug-induced deaths, 1995 to 2010 /stats12/drdtab2a drdtab2a Table-DRD-02-parti.xml
Table DRD drdtab2 2 ii Number of drug-induced deaths recorded in EU Member States according to national definitions Male drug-induced deaths, 1995 to 2010 /stats12/drdtab2b drdtab2b Table-DRD-02-partii.xml
Table DRD drdtab2 2 iii Number of drug-induced deaths recorded in EU Member States according to national definitions Female drug-induced deaths, 1995 to 2010 /stats12/drdtab2c drdtab2c Table-DRD-02-partiii.xml
Table DRD drdtab2 2 iv Number of drug-induced deaths recorded in EU Member States according to national definitions Total drug-induced deaths under the age of 25 years, 1995 to 2010 /stats12/drdtab2d drdtab2d Table-DRD-02-partiv.xml
Table DRD drdtab2 2 v Number of drug-induced deaths recorded in EU Member States according to national definitions Totals and indexes, 1995 to 2010 /stats12/drdtab2e drdtab2e Table-DRD-02-partv.xml
Table DRD drdtab3 3   Number of drug-induced deaths recorded in EU Member States and Norway according to EMCDDA standard definition 'Selection B', 1995 to 2010   /stats12/drdtab3 drdtab3 Table-DRD-03-part0.xml
Table DRD drdtab4 4   Number of drug-induced deaths recorded in EU Member States according to EMCDDA standard definition 'Selection D', 1995 to 2010   /stats12/drdtab4 drdtab4 Table-DRD-04-part0.xml
Table DRD drdtab5 5 i Mortality due to drug-induced deaths in European countries, in all adults and adults aged 15 to 39 years (total and males) Population mortality rates, 2010 or last year with available information /stats12/drdtab5a drdtab5a Table-DRD-05-parti.xml
Table DRD drdtab5 5 ii Mortality due to drug-induced deaths in European countries, in all adults and adults aged 15 to 39 years (total and males) Proportional mortality due to drug-induced deaths, 2009 or last year with available information. /stats12/drdtab5b drdtab5b Table-DRD-05-partii.xml
Table DRD drdtab5 5 iii Mortality due to drug-induced deaths in European countries, in all adults and adults aged 15 to 39 years (total and males) Estimated mortality (numbers and population rates) due to AIDS attributable to injection drug use /stats12/drdtab5c drdtab5c Table-DRD-05-partiii.xml
Table DRD drdtab106 106   Methodological features of drug-induced deaths reported by National Reitox Focal Points (Based on national definitions - Reitox Standard Table 5)   /stats12/drdtab106 drdtab106 Table-DRD-106-part0.xml
Table DRD drdtab107 107 i Number of drug-induced deaths recorded in EU Member States according to national definitions Total drug-induced deaths, 1985 to 2010 /stats12/drdtab107a drdtab107a Table-DRD-107-parti.xml
Table DRD drdtab107 107 ii Number of drug-induced deaths recorded in EU Member States according to national definitions Totals and indexes, 1985 to 2010 /stats12/drdtab107b drdtab107b Table-DRD-107-partii.xml
Table DRD drdtab108 108   Drug-induced deaths: Detailed qualitative national information on deaths due to specific substances in EU Member States (2011 National Reports)   /stats12/drdtab108 drdtab108 Table-DRD-108-part0.xml
Figure DRD drdfig1 1   Proportion of drug-induced deaths that show presence of opioids for the most recent year reported   /stats12/drdfig1 drdfig1 Table-DRD-g01-part0.xml
Figure DRD drdfig2 2   Proportion of drug-induced deaths occurring under the age of 25 years for the most recent year reported   /stats12/drdfig2 drdfig2 Table-DRD-g02-part0.xml
Figure DRD drdfig3 3   Trends in mean age of drug-induced deaths in some of the EU-15 Member States, 1990 to 2010   /stats12/drdfig3 drdfig3 Table-DRD-g03-part0.xml
Figure DRD drdfig4 4   Trends in mean age of drug-induced deaths in some new EU Member States, 1990 to 2010   /stats12/drdfig4 drdfig4 Table-DRD-g04-part0.xml
Figure DRD drdfig5 5 i lndexed trends in drug-induced deaths and in the numbers of deaths occurring under the age of 25 Indexed trend in the EU-15 Member States and Norway 1990–2009 /stats12/drdfig5a drdfig5a Table-DRD-g05-parti.xml
Figure DRD drdfig5 5 ii lndexed trends in drug-induced deaths and in the numbers of deaths occurring under the age of 25 Indexed trend in the new Member States, 1990–2009 /stats12/drdfig5b drdfig5b Table-DRD-g05-partii.xml
Figure DRD drdfig6 6   Indexed overall trends for males and females in drug-induced deaths in the EU-15 Member States and Norway, 1990 to 2009   /stats12/drdfig6 drdfig6 Table-DRD-g06-part0.xml
Figure DRD drdfig7 7 i Mortality due to drug-induced deaths among all adults (15 to 64 years) in European countries for the most recent year reported Mortality rates per million among all adults (15 to 64 years) due to drug-related deaths /stats12/drdfig7a drdfig7a Table-DRD-g07-parti.xml
Figure DRD drdfig7 7 ii Mortality due to drug-induced deaths among all adults (15 to 64 years) in European countries for the most recent year reported Mortality rates among all adults (15 to 64 years) due to drug-related deaths and estimated mortality rates due to HIV/AIDS attributable to injection drug use /stats12/drdfig7b drdfig7b Table-DRD-g07-partii.xml
Figure DRD drdfig8 8   Indexed long term trend in drug-induced deaths in the EU-15 Member States and Norway, 1985 to 2009   /stats12/drdfig8 drdfig8 Table-DRD-g08-part0.xml
Figure DRD drdfig9 9 i Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the Member States, 1990 to 2010 (three-year moving average) Some EU Member States and Norway, 1990 to 2010 /stats12/drdfig9a drdfig9a Table-DRD-g09-parti.xml
Figure DRD drdfig9 9 ii Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the Member States, 1990 to 2010 (three-year moving average) Some EU Member States, 1990 to 2010 /stats12/drdfig9b drdfig9b Table-DRD-g09-partii.xml
Figure DRD drdfig9 9 iii Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the Member States, 1990 to 2010 (three-year moving average) Some EU countries, 1990 to 2010 /stats12/drdfig9c drdfig9c Table-DRD-g09-partiii.xml
Figure DRD drdfig10 10   Mean age of drug-induced deaths in EU Member States, last year with available data   /stats12/drdfig10 drdfig10 Table-DRD-g10-part0.xml
Figure DRD drdfig11 11 i Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole Index in some Member States, 1985 to 2010 /stats12/drdfig11a drdfig11a Table-DRD-g11-parti.xml
Figure DRD drdfig11 11 ii Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole Index in some Member States, 1985 to 2010 /stats12/drdfig11b drdfig11b Table-DRD-g11-partii.xml
Figure DRD drdfig11 11 iii Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole Index in some Member States, 1985 to 2010 /stats12/drdfig11c drdfig11c Table-DRD-g11-partiii.xml
Figure DRD drdfig12 12 i Changes in numbers and ratio of drug-induced deaths in the EU Member States, Croatia and Norway Changes between 2000 and 2003 /stats12/drdfig12a drdfig12a Table-DRD-g12-parti.xml
Figure DRD drdfig12 12 ii Changes in numbers and ratio of drug-induced deaths in the EU Member States, Croatia and Norway Changes between 2003 and 2009/10 /stats12/drdfig12b drdfig12b Table-DRD-g12-partii.xml
Figure DRD drdfig13 13 i Number of drug-induced deaths recorded in EU Member States occurring under the age of 25 according to national definitions. EU-15 Member States and Norway 1990–2009 /stats12/drdfig13a drdfig13a Table-DRD-g13-parti.xml
Figure DRD drdfig13 13 ii Number of drug-induced deaths recorded in EU Member States occurring under the age of 25 according to national definitions. New Member States, 1990–2009 /stats12/drdfig13b drdfig13b Table-DRD-g13-partii.xml
Table DUP duptab0 0   Prevalence of drug use among prisoners — Sources and bibliographic references   /stats12/duptab0 duptab0 Table-DUP-00-parti.xml
Table DUP duptab1 1   Prevalence of lifetime drug use among prisoners, 2000–2010   /stats12/duptab1 duptab1 Table-DUP-01-parti.xml
Table DUP duptab2 2   Prevalence of lifetime injecting drug use among prisoners, 2000–2010   /stats12/duptab2 duptab2 Table-DUP-02-parti.xml
Table DUP duptab3 3   Prevalence of drug use within prison among prisoners, 2000–2010   /stats12/duptab3 duptab3 Table-DUP-03-parti.xml
Table DUP duptab4 4   Prevalence of injecting drug use within prison among prisoners, 2000–2010   /stats12/duptab4 duptab4 Table-DUP-04-parti.xml
Table DUP duptab105 105   Prevalence (percentage) of drug use among prisoners in EU member states and Norway - full listing of studies   /stats12/duptab105 duptab105 Table-DUP-105-part0.xml
Table EYE eyetab0 0   School surveys: Sources   /stats12/eyetab0 eyetab0 Table-EYE-00-part0.xml
Table EYE eyetab08 08   HBSC school surveys (2009/10): percentage lifetime prevalence of cannabis use among students aged 15–16 years old   /stats12/eyetab08 eyetab08 Table-EYE-08-part0.xml
Table EYE eyetab9 9 i HBSC school surveys (2009/10): percentage lifetime prevalence of cannabis use among students aged 15–16 years old HBSC school surveys (2009/10) All students /stats12/eyetab9a eyetab9a Table-EYE-09-parti.xml
Table EYE eyetab9 9 ii HBSC school surveys (2009/10): percentage lifetime prevalence of cannabis use among students aged 15–16 years old HBSC school surveys (2009/10) Males /stats12/eyetab9b eyetab9b Table-EYE-09-partii.xml
Table EYE eyetab9 9 iii HBSC school surveys (2009/10) percentage lifetime prevalence of cannabis use among students aged 15–16 years old HBSC school surveys (2009/10) Females /stats12/eyetab9c eyetab9c Table-EYE-09-partiii.xml
Table EYE eyetab10 10   Recent school surveys (2005-2011): percentage lifetime prevalence of psychoactive substance use among students aged 15–16 years old   /stats12/eyetab10 eyetab10 Table-EYE-10-part0.xml
Table EYE eyetab11 11   School surveys: percentage lifetime prevalence of psychoactive substance use among students aged 15–16 years   /stats12/eyetab11 eyetab11 Table-EYE-11-part0.xml
Table EYE eyetab20 20 i ESPAD 2011 school surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years All students /stats12/eyetab20a eyetab20a Table-EYE-20-parti.xml
Table EYE eyetab20 20 ii ESPAD 2011 school surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years Males /stats12/eyetab20b eyetab20b Table-EYE-20-partii.xml
Table EYE eyetab20 20 iii ESPAD 2011 school surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years Females /stats12/eyetab20c eyetab20c Table-EYE-20-partiii.xml
Table EYE eyetab21 21 i ESPAD 2011 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15–16 years All students /stats12/eyetab21a eyetab21a Table-EYE-21-parti.xml
Table EYE eyetab21 21 ii ESPAD 2011 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15–16 years Males /stats12/eyetab21b eyetab21b Table-EYE-21-partii.xml
Table EYE eyetab21 21 iii ESPAD 2011 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15–16 years Females /stats12/eyetab21c eyetab21c Table-EYE-21-partiii.xml
Table EYE eyetab22 22 i All ESPAD School Surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years All students /stats12/eyetab22a eyetab22a Table-EYE-22-parti.xml
Table EYE eyetab22 22 ii All ESPAD School Surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years Males /stats12/eyetab22b eyetab22b Table-EYE-22-partii.xml
Table EYE eyetab22 22 iii All ESPAD School Surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years Females /stats12/eyetab22c eyetab22c Table-EYE-22-partiii.xml
Table EYE eyetab23 23 i All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15–16 years All students /stats12/eyetab23a eyetab23a Table-EYE-23-parti.xml
Table EYE eyetab23 23 ii All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15–16 years Males /stats12/eyetab23b eyetab23b Table-EYE-23-partii.xml
Table EYE eyetab23 23 iii All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15–16 years Females /stats12/eyetab23c eyetab23c Table-EYE-23-partiii.xml
Table EYE eyetab30 30   Recent School Surveys (2003-2011): percentage lifetime prevalence of psychoactive substance use and last month prevalence of cannabis among students aged 17-18 years old   /stats12/eyetab30 eyetab30 Table-EYE-30-part0.xml
Figure EYE eyefig1 1 i Cannabis prevalence rates, ESPAD 2011 Different patterns in trends in lifetime prevalence of cannabis use among 15- to 16-year-old school students over the five rounds of the ESPAD survey /stats12/eyefig1a eyefig1a Table-EYE-g01-parti.xml
Figure EYE eyefig1 1 ii Cannabis prevalence rates, ESPAD 2011 Different patterns in trends in lifetime prevalence of cannabis use among 15- to 16-year-old school students over the five rounds of the ESPAD survey /stats12/eyefig1b eyefig1b Table-EYE-g01-partii.xml
Figure EYE eyefig1 1 iii Cannabis prevalence rates, ESPAD 2011 Different patterns in trends in lifetime prevalence of cannabis use among 15- to 16-year-old school students over the five rounds of the ESPAD survey /stats12/eyefig1c eyefig1c Table-EYE-g01-partiii.xml
Figure EYE eyefig1 1 iv Cannabis prevalence rates, ESPAD 2011 Comparison of lifetime prevalence of cannabis use with perceived great risk (percentages), among 15/16 year olds school students in 2007/2011 /stats12/eyefig1d eyefig1d Table-EYE-g01-partiv.xml
Table GPS gpstab0 0   Nationwide surveys among the general population: Bibliographic references   /stats12/gpstab0 gpstab0 Table-GPS-00-part0.xml
Table GPS gpstab1 1 i Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000. Survey methods. /stats12/gpstab1a gpstab1a Table-GPS-01-parti.xml
Table GPS gpstab1 1 ii Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000. All adults (aged 15 - 64). /stats12/gpstab1b gpstab1b Table-GPS-01-partii.xml
Table GPS gpstab1 1 iii Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000. Young adults (aged 15 - 34). /stats12/gpstab1c gpstab1c Table-GPS-01-partiii.xml
Table GPS gpstab1 1 iv Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000. Youth (15 - 24). /stats12/gpstab1d gpstab1d Table-GPS-01-partiv.xml
Table GPS gpstab2 2 i Last 12 months prevalence of drug use by age and country, most recent national general population survey available since 2000. All adults (aged 15 - 64). /stats12/gpstab2a gpstab2a Table-GPS-02-parti.xml
Table GPS gpstab2 2 ii Last 12 months prevalence of drug use by age and country, most recent national general population survey available since 2000. Young adults (15 - 34). /stats12/gpstab2b gpstab2b Table-GPS-02-partii.xml
Table GPS gpstab2 2 iii Last 12 months prevalence of drug use by age and country, most recent national general population survey available since 2000. Youth (aged 15 - 24). /stats12/gpstab2c gpstab2c Table-GPS-02-partiii.xml
Table GPS gpstab3 3 i Last 30 days prevalence of drug use by age and country, most recent national general population survey available since 2000. All adults (aged 15 - 64). /stats12/gpstab3a gpstab3a Table-GPS-03-parti.xml
Table GPS gpstab3 3 ii Last 30 days prevalence of drug use by age and country, most recent national general population survey available since 2000. Young adults (15 - 34). /stats12/gpstab3b gpstab3b Table-GPS-03-partii.xml
Table GPS gpstab3 3 iii Last 30 days prevalence of drug use by age and country, most recent national general population survey available since 2000. Youth (aged 15 - 24). /stats12/gpstab3c gpstab3c Table-GPS-03-partiii.xml
Table GPS gpstab4 4 i Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. All adults male (aged 15 - 64). /stats12/gpstab4a gpstab4a Table-GPS-04-parti.xml
Table GPS gpstab4 4 ii Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. All adults female (aged 15 - 64). /stats12/gpstab4b gpstab4b Table-GPS-04-partii.xml
Table GPS gpstab4 4 iii Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. Young adults male (aged 15 - 34). /stats12/gpstab4c gpstab4c Table-GPS-04-partiii.xml
Table GPS gpstab4 4 iv Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. Young adults female (aged 15 - 34). /stats12/gpstab4d gpstab4d Table-GPS-04-partiv.xml
Table GPS gpstab4 4 v Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. Youth male (aged 15 - 24). /stats12/gpstab4e gpstab4e Table-GPS-04-partv.xml
Table GPS gpstab4 4 vi Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. Youth female (aged 15 - 24). /stats12/gpstab4f gpstab4f Table-GPS-04-partvi.xml
Table GPS gpstab5 5 i Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. All adults male (aged 15 - 64). /stats12/gpstab5a gpstab5a Table-GPS-05-parti.xml
Table GPS gpstab5 5 ii Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. All adults female (aged 15 - 64). /stats12/gpstab5b gpstab5b Table-GPS-05-partii.xml
Table GPS gpstab5 5 iii Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. Young adults male (aged 15 - 34). /stats12/gpstab5c gpstab5c Table-GPS-05-partiii.xml
Table GPS gpstab5 5 iv Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. Young adults female (aged 15 - 34). /stats12/gpstab5d gpstab5d Table-GPS-05-partiv.xml
Table GPS gpstab5 5 v Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. Youth male (aged 15 - 24). /stats12/gpstab5e gpstab5e Table-GPS-05-partv.xml
Table GPS gpstab5 5 vi Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. Youth female (aged 15 - 24). /stats12/gpstab5f gpstab5f Table-GPS-05-partvi.xml
Table GPS gpstab6 6 i Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. All adults male (aged 15 - 64). /stats12/gpstab6a gpstab6a Table-GPS-06-parti.xml
Table GPS gpstab6 6 ii Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. All adults female (aged 15 - 64). /stats12/gpstab6b gpstab6b Table-GPS-06-partii.xml
Table GPS gpstab6 6 iii Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. Young adults male (aged 15 - 34). /stats12/gpstab6c gpstab6c Table-GPS-06-partiii.xml
Table GPS gpstab6 6 iv Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. Young adults female (aged 15 - 34). /stats12/gpstab6d gpstab6d Table-GPS-06-partiv.xml
Table GPS gpstab6 6 v Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. Youth male (aged 15 - 24). /stats12/gpstab6e gpstab6e Table-GPS-06-partv.xml
Table GPS gpstab6 6 vi Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000. Youth female (aged 15 - 24). /stats12/gpstab6f gpstab6f Table-GPS-06-partvi.xml
Table GPS gpstab7 7 i Lifetime prevalence of drug use in all available national general population surveys. Survey methods. /stats12/gpstab7a gpstab7a Table-GPS-07-parti.xml
Table GPS gpstab7 7 ii Lifetime prevalence of drug use in all available national general population surveys. All adults (aged 15 -64). /stats12/gpstab7b gpstab7b Table-GPS-07-partii.xml
Table GPS gpstab7 7 iii Lifetime prevalence of drug use in all available national general population surveys. Young adults (aged 15 -34). /stats12/gpstab7c gpstab7c Table-GPS-07-partiii.xml
Table GPS gpstab7 7 iv Lifetime prevalence of drug use in all available national general population surveys. Youth (aged 15 - 24). /stats12/gpstab7d gpstab7d Table-GPS-07-partiv.xml
Table GPS gpstab8 8 i Last 12 months prevalence of drug use in all available national general population surveys. All adults (aged 15 - 64). /stats12/gpstab8a gpstab8a Table-GPS-08-parti.xml
Table GPS gpstab8 8 ii Last 12 months prevalence of drug use in all available national general population surveys. Young adults (15 - 34). /stats12/gpstab8b gpstab8b Table-GPS-08-partii.xml
Table GPS gpstab8 8 iii Last 12 months prevalence of drug use in all available national general population surveys. Youth (aged 15 - 24). /stats12/gpstab8c gpstab8c Table-GPS-08-partiii.xml
Table GPS gpstab9 9 i Last 30 days prevalence of drug use in all available national general population surveys. All adults (aged 15 - 64). /stats12/gpstab9a gpstab9a Table-GPS-09-parti.xml
Table GPS gpstab9 9 ii Last 30 days prevalence of drug use in all available national general population surveys. Young adults (15 - 34). /stats12/gpstab9b gpstab9b Table-GPS-09-partii.xml
Table GPS gpstab9 9 iii Last 30 days prevalence of drug use in all available national general population surveys. Youth (aged 15 - 24). /stats12/gpstab9c gpstab9c Table-GPS-09-partiii.xml
Table GPS gpstab10 10 i Frequency of use of cannabis amongst users in the last 30 days in national general population surveys. All adults (aged 15 - 64) - most recent data. /stats12/gpstab10a gpstab10a Table-GPS-10-parti.xml
Table GPS gpstab10 10 ii Frequency of use of cannabis amongst users in the last 30 days in national general population surveys. All adults (aged 15 - 64) - 2007 field trial. /stats12/gpstab10b gpstab10b Table-GPS-10-partii.xml
Table GPS gpstab10 10 iii Frequency of use of cannabis amongst users in the last 30 days in national general population surveys. All adults (aged 15 - 64) - 2004 field trial. /stats12/gpstab10c gpstab10c Table-GPS-10-partiii.xml
Table GPS gpstab10 10 iv Frequency of use of cannabis amongst users in the last 30 days in national general population surveys. Young adults (aged 15 - 34) - combined sources. /stats12/gpstab10d gpstab10d Table-GPS-10-partiv.xml
Table GPS gpstab121 121   Methodological information for nation-wide surveys among the general population   /stats12/gpstab121 gpstab121 Table-GPS-121-part0.xml
Figure GPS gpsfig1 1   Last 12 months prevalence of cannabis use among all adults (aged 15 - 64), young adults (aged 15 - 34) and for youth (aged 15 - 24)   /stats12/gpsfig1 gpsfig1 Table-GPS-g01-part0.xml
Figure GPS gpsfig2 2   Continuation rates of cannabis use (last 12 months use and last 30 days use as proportions of lifetime use)   /stats12/gpsfig2 gpsfig2 Table-GPS-g02-part0.xml
Figure GPS gpsfig3 3   Last 30 days prevalence of cannabis use among youth (aged 15 - 24)   /stats12/gpsfig3 gpsfig3 Table-GPS-g03-part0.xml
Figure GPS gpsfig4 4 i Trends in last 12 months prevalence of cannabis use among young adults (aged 15 - 34) All countries /stats12/gpsfig4a gpsfig4a Table-GPS-g04-parti.xml
Figure GPS gpsfig4 4 ii Trends in last 12 months prevalence of cannabis use among young adults (aged 15 - 34) Countries with three or more surveys /stats12/gpsfig4b gpsfig4b Table-GPS-g04-partii.xml
Figure GPS gpsfig5 5   Last 12 months prevalence of amphetamines use among young adults (aged 15 - 34) and youth (aged 15 - 24)   /stats12/gpsfig5 gpsfig5 Table-GPS-g05-part0.xml
Figure GPS gpsfig6 6   Last 12 months prevalence of amphetamines use among all adults (aged 15 - 64), young adults (aged 15 - 34) and youth (aged 15 - 24)   /stats12/gpsfig6 gpsfig6 Table-GPS-g06-part0.xml
Figure GPS gpsfig7 7   Last 30 days prevalence of cannabis use among all adults (aged 15 - 64), young adults (aged 15 - 34) and youth (aged 15 - 24)   /stats12/gpsfig7 gpsfig7 Table-GPS-g07-part0.xml
Figure GPS gpsfig8 8 i Trends in last 12 months use of amphetamines among young adults (aged 15 - 34) All countries /stats12/gpsfig8a gpsfig8a Table-GPS-g08-parti.xml
Figure GPS gpsfig8 8 ii Trends in last 12 months use of amphetamines among young adults (aged 15 - 34) Countries with three or more surveys /stats12/gpsfig8b gpsfig8b Table-GPS-g08-partii.xml
Figure GPS gpsfig9 9 i Last 12 months prevalence of ecstasy use among all adults (aged 15 - 64), young adults (aged 15 - 34) and youth (aged 15 - 24) All age groups /stats12/gpsfig9a gpsfig9a Table-GPS-g09-parti.xml
Figure GPS gpsfig9 9 ii Last 12 months prevalence of ecstasy use among all adults (aged 15 - 64), young adults (aged 15 - 34) and youth (aged 15 - 24) Males aged 15 to 24 in countries with high prevalence rates /stats12/gpsfig9b gpsfig9b Table-GPS-g09-partii.xml
Figure GPS gpsfig10 10   Last 12 months prevalence of cannabis use by age group in United Kingdom (E&W)   /stats12/gpsfig10 gpsfig10 Table-GPS-g10-part0.xml
Figure GPS gpsfig11 11   Continuation rates of ecstasy use (last 12 months use and last 30 days use as proportions of lifetime use)   /stats12/gpsfig11 gpsfig11 Table-GPS-g11-part0.xml
Figure GPS gpsfig12 12 i Last 12 months prevalence of cannabis use by age group Selected EU-15 countries /stats12/gpsfig12a gpsfig12a Table-GPS-g12-parti.xml
Figure GPS gpsfig12 12 ii Last 12 months prevalence of cannabis use by age group Selected 'new' EU countries /stats12/gpsfig12b gpsfig12b Table-GPS-g12-partii.xml
Figure GPS gpsfig13 13   Last 12 months prevalence of cocaine use among young adults (aged 15 - 34) by gender   /stats12/gpsfig13 gpsfig13 Table-GPS-g13-part0.xml
Figure GPS gpsfig14 14 i Trends in last 12 months prevalence of cocaine use among young adults (aged 15 - 34) All countries /stats12/gpsfig14a gpsfig14a Table-GPS-g14-parti.xml
Figure GPS gpsfig14 14 ii Trends in last 12 months prevalence of cocaine use among young adults (aged 15 - 34) Countries with three or more surveys /stats12/gpsfig14b gpsfig14b Table-GPS-g14-partii.xml
Figure GPS gpsfig15 15   Last 12 months prevalence of cocaine use among all adults (aged 15 - 64), young adults (aged 15 - 34) and youth (aged 15 - 24)   /stats12/gpsfig15 gpsfig15 Table-GPS-g15-part0.xml
Figure GPS gpsfig16 16   Continuation rates of cocaine use (last 12 months use and last 30 days use as proportions of lifetime use)   /stats12/gpsfig16 gpsfig16 Table-GPS-g16-part0.xml
Figure GPS gpsfig17 17   Last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 - 34)   /stats12/gpsfig17 gpsfig17 Table-GPS-g17-part0.xml
Figure GPS gpsfig18 18 i Overview of drug prevalence estimates in Europe for all adults (aged 15 - 64) and young adults (aged 15 - 34) Cannabis use – lifetime experience, last 12 months and last 30 days prevalence /stats12/gpsfig18a gpsfig18a Table-GPS-g18-parti.xml
Figure GPS gpsfig18 18 ii Overview of drug prevalence estimates in Europe for all adults (aged 15 - 64) and young adults (aged 15 - 34) Cocaine, amphetamines and ecstasy use – lifetime experience, last 12 months and last 30 days prevalence /stats12/gpsfig18b gpsfig18b Table-GPS-g18-partii.xml
Figure GPS gpsfig20 20   Lifetime and last 12 months prevalence of cocaine use among young adults (aged 15 - 34) in Europe, Canada, Australia and the USA   /stats12/gpsfig20 gpsfig20 Table-GPS-g20-part0.xml
Figure GPS gpsfig21 21 i Trends in last 12 months prevalence of ecstasy use among young adults (aged 15 - 34) All countries /stats12/gpsfig21a gpsfig21a Table-GPS-g21-parti.xml
Figure GPS gpsfig21 21 ii Trends in last 12 months prevalence of ecstasy use among young adults (aged 15 - 34) Countries with three or more surveys /stats12/gpsfig21b gpsfig21b Table-GPS-g21-partii.xml
Figure GPS gpsfig22 22   Continuation rates of amphetamine use (last 12 months use and last 30 days use as proportions of lifetime use)   /stats12/gpsfig22 gpsfig22 Table-GPS-g22-part0.xml
Figure GPS gpsfig23 23 i Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 - 34) United Kingdom (E&W) /stats12/gpsfig23a gpsfig23a Table-GPS-g23-parti.xml
Figure GPS gpsfig23 23 ii Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 - 34) Denmark /stats12/gpsfig23b gpsfig23b Table-GPS-g23-partii.xml
Figure GPS gpsfig23 23 iii Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 - 34) Germany /stats12/gpsfig23c gpsfig23c Table-GPS-g23-partiii.xml
Figure GPS gpsfig23 23 iv Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 - 34) Spain /stats12/gpsfig23d gpsfig23d Table-GPS-g23-partiv.xml
Figure GPS gpsfig23 23 v Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 - 34) France /stats12/gpsfig23e gpsfig23e Table-GPS-g23-partv.xml
Table HSR hsrtab1 1   Year of introduction of methadone maintenance treatment (MMT), high-dosage buprenorphine treatment (HDBT), buprenorphine/naloxone combination, heroin-assisted treatment and slow-release morphine   /stats12/hsrtab1 hsrtab1 Table-HSR-01-part0.xml
Table HSR hsrtab2 2 i Legal framework of opioid substitution treatment initiation, continuation and dispensing (by substitution medication) in EU-27, Croatia, Turkey and Norway Legal framework regarding the initiation of OST by substitution medication /stats12/hsrtab2a hsrtab2a Table-HSR-02-parti.xml
Table HSR hsrtab2 2 ii Legal framework of opioid substitution treatment initiation, continuation and dispensing (by substitution medication) in EU-27, Croatia, Turkey and Norway Legal framework regarding the continuation of OST by substitution medication /stats12/hsrtab2b hsrtab2b Table-HSR-02-partii.xml
Table HSR hsrtab2 2 iii Legal framework of opioid substitution treatment initiation, continuation and dispensing (by substitution medication) in EU-27, Croatia, Turkey and Norway Legal framework regarding the dispensing of substitution medications /stats12/hsrtab2c hsrtab2c Table-HSR-02-partiii.xml
Table HSR hsrtab3 3 i Estimated number of clients in methadone treatment and of all clients receiving any opioid substitution treatment (OST) Estimates of clients in methadone treatment or any opioid substitution in EU-27, Croatia, Turkey and Norway, 1993 - 2010 /stats12/hsrtab3a hsrtab3a Table-HSR-03-parti.xml
Table HSR hsrtab3 3 ii Estimated number of clients in methadone treatment and of all clients receiving any opioid substitution treatment (OST) Estimates and share of clients in methadone (MMT) and buprenorphine-based opioid substitution treatment in EU-27, Croatia, Turkey and Norway in 2010 or latest available year /stats12/hsrtab3b hsrtab3b Table-HSR-03-partii.xml
Table HSR hsrtab3 3 iii Estimated number of clients in methadone treatment and of all clients receiving any opioid substitution treatment (OST) Methodological notes EU-27, Croatia, Turkey and Norway, 2003 - 2010 /stats12/hsrtab3c hsrtab3c Table-HSR-03-partiii.xml
Table HSR hsrtab4 4 i Needle and syringe programmes (NSPs) Year of introduction of needle and syringe programmes (NSPs), types of programmes available in 2010 and number of sites /stats12/hsrtab4a hsrtab4a Table-HSR-04-parti.xml
Table HSR hsrtab4 4 ii Needle and syringe programmes (NSPs) NSP geographical coverage, 2010 or latest available year /stats12/hsrtab4b hsrtab4b Table-HSR-04-partii.xml
Table HSR hsrtab5 5 i Provision of needle and syringe programmes (NSPs) Syringes provided through needle and syringe programmes (NSPs), 2003-2010 /stats12/hsrtab5a hsrtab5a Table-HSR-05-parti.xml
Table HSR hsrtab5 5 ii Provision of needle and syringe programmes (NSPs) Clients and contacts at specialist NSP agencies, 2009-2010 /stats12/hsrtab5b hsrtab5b Table-HSR-05-partii.xml
Table HSR hsrtab6 6 i Hepatitis responses in Europe Hepatitis B immunization in EU27, Croatia, Turkey and Norway /stats12/hsrtab6a hsrtab6a Table-HSR-06-parti.xml
Table HSR hsrtab6 6 ii Hepatitis responses Availability of Hepatitis C testing in EU27, Croatia, Turkey and Norway /stats12/hsrtab6b hsrtab6b Table-HSR-06-partii.xml
Table HSR hsrtab7 7   Availability of selected health responses in prison in EU-27, Croatia, Turkey and Norway   /stats12/hsrtab7 hsrtab7 Table-HSR-07-part0.xml
Table HSR hsrtab8 8 i Responses to drug related deaths in Europe Availability of selected responses to reduce drug related deaths in 27 EU countries, Norway and Turkey (expert ratings) /stats12/hsrtab8a hsrtab8a Table-HSR-08-parti.xml
Table HSR hsrtab8 8 ii Responses to drug related deaths in Europe Availability of information material on drug-related deaths and emergencies for specific target groups in 27 EU countries, Norway and Turkey /stats12/hsrtab8b hsrtab8b Table-HSR-08-partii.xml
Table HSR hsrtab9 9   Opioid substitution treatment in prison in EU 27, Croatia, Turkey and Norway   /stats12/hsrtab9 hsrtab9 Table-HSR-09-part0.xml
Table HSR hsrtab10 10   Estimation of the total number of clients in treatment in 2010 or latest available year   /stats12/hsrtab10 hsrtab10 Table-HSR-10-part0.xml
Figure HSR hsrfig1 1 i Opioid substitution treatment coverage Opioid substitution treatment clients as a percentage of the estimated number of problem opioid users, 2010 or most recent year available /stats12/hsrfig1a hsrfig1a Table-HSR-g01-parti.xml
Figure HSR hsrfig1 1 ii Opioid substitution treatment coverage Overall estimated number of problem opioid users in treatment (in opioid substitution treatment and other treatments) as a percentage of the estimated number of problem opioid users, 2010 or most recent year available /stats12/hsrfig1b hsrfig1b Table-HSR-g01-partii.xml
Figure HSR hsrfig2 2   Estimated number of clients in opioid substitution treatment (OST) in EU15-12, 1993 - 2010.   /stats12/hsrfig2 hsrfig2 Table-HSR-g02-part0.xml
Figure HSR hsrfig3 3   Syringes distributed through specialised programmes in 2010 per estimated IDU   /stats12/hsrfig3 hsrfig3 Table-HSR-g03-part0.xml
Figure HSR hsrfig4 4   Proportion of prison population receiving opioid substitution treatment (OST) on a given day in 2010 or latest available year   /stats12/hsrfig4 hsrfig4 Table-HSR-g04-part0.xml
Table INF inftab0 0   Bibliographic references   /stats12/inftab0 inftab0 Table-INF-00-part0.xml
Table INF inftab1 1   Prevalence of HIV infection among injecting drug users in the EU countries, Croatia, Turkey and Norway, 2010 or most recent year available - Summary table by country   /stats12/inftab1 inftab1 Table-INF-01-part0.xml
Table INF inftab2 2   Prevalence of HCV antibody among injecting drug users in the EU countries, Croatia, Turkey and Norway, 2010 or most recent year available - Summary table by country   /stats12/inftab2 inftab2 Table-INF-02-part0.xml
Table INF inftab3 3   Prevalence of markers for HBV infection among injecting drug users in the EU countries, Croatia, Turkey and Norway, 2010 or most recent year available - Summary table by country   /stats12/inftab3 inftab3 Table-INF-03-part0.xml
Table INF inftab104 104 i HIV infections newly diagnosed and AIDS diagnosed among injecting drug users, by country and year of diagnosis HIV infection in the EU countries, Croatia, Turkey and Norway: (a) cases per million population, (b) number of cases and (c) population sizes /stats12/inftab104a inftab104a Table-INF-104-parti.xml
Table INF inftab104 104 ii HIV infections newly diagnosed and AIDS diagnosed among injecting drug users, by country and year of diagnosis HIV infection in non-EU countries of the WHO European region: (a) cases per million population, (b) number of cases and (c) population sizes /stats12/inftab104b inftab104b Table-INF-104-partii.xml
Table INF inftab104 104 iii HIV infections newly diagnosed and AIDS diagnosed among injecting drug users, by country and year of diagnosis AIDS incidence in the EU countries, Croatia, Turkey and Norway: (a) cases per million population, (b) number of cases and (c) population sizes /stats12/inftab104c inftab104c Table-INF-104-partiii.xml
Table INF inftab104 104 iv HIV infections newly diagnosed and AIDS diagnosed among injecting drug users, by country and year of diagnosis AIDS incidence in non-EU countries of the WHO European region: (a) cases per million population, (b) number of cases and (c) population sizes /stats12/inftab104d inftab104d Table-INF-104-partiv.xml
Table INF inftab105 105 i Notified cases of hepatitis C infection among injecting drug users in the EU countries, Croatia and Norway Total number of cases where transmission route known, number of IDU cases, and percentage of IDUs amongst all cases with known risk factor /stats12/inftab105a inftab105a Table-INF-105-parti.xml
Table INF inftab105 105 ii Notified cases of hepatitis C infection among injecting drug users in the EU countries, Croatia and Norway Case definitions /stats12/inftab105b inftab105b Table-INF-105-partii.xml
Table INF inftab106 106 i Notified cases of hepatitis B infection among injecting drug users in the EU countries, Croatia and Norway Total number of cases where transmission route known, number of IDU cases, and percentage of IDUs amongst all cases with known risk factor /stats12/inftab106a inftab106a Table-INF-106-parti.xml
Table INF inftab106 106 ii Notified cases of hepatitis B infection among injecting drug users in the EU countries, Croatia and Norway Case definitions /stats12/inftab106b inftab106b Table-INF-106-partii.xml
Table INF inftab108 108   Prevalence of HIV infection among injecting drug users (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway   /stats12/inftab108 inftab108 Table-INF-108-part0.xml
Table INF inftab109 109   Prevalence of HIV infection among injecting drug users under age 25 (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway   /stats12/inftab109 inftab109 Table-INF-109-part0.xml
Table INF inftab110 110   Prevalence of HIV infection among new (injecting less than 2 years) injecting drug users (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway   /stats12/inftab110 inftab110 Table-INF-110-part0.xml
Table INF inftab111 111   Prevalence of hepatitis C infection among injecting drug users (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway   /stats12/inftab111 inftab111 Table-INF-111-part0.xml
Table INF inftab112 112   Prevalence of hepatitis C infection among injecting drug users under age 25 (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway   /stats12/inftab112 inftab112 Table-INF-112-part0.xml
Table INF inftab113 113   Prevalence of hepatitis C infection among new (injecting less than 2 years) injecting drug users (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway   /stats12/inftab113 inftab113 Table-INF-113-part0.xml
Table INF inftab114 114   Prevalence of current hepatitis B infection among injecting drug users (% with HBsAg), 1991 to 2010. EU countries, Croatia, Turkey and Norway   /stats12/inftab114 inftab114 Table-INF-114-part0.xml
Table INF inftab115 115   Prevalence of antibodies against hepatitis B virus among injecting drug users (%), 1991 to 2009. EU countries, Croatia, Turkey and Norway   /stats12/inftab115 inftab115 Table-INF-115-part0.xml
Figure INF inffig1 1 i AIDS incidence by year of diagnosis among injecting drug users by country, cases per million 1998 to 2010 EU countries, Croatia, Turkey and Norway /stats12/inffig1a inffig1a Table-INF-g01-parti.xml
Figure INF inffig1 1 ii AIDS incidence by year of diagnosis among injecting drug users by country, cases per million 1998 to 2010 Non-EU countries of the WHO European region /stats12/inffig1b inffig1b Table-INF-g01-partii.xml
Figure INF inffig2 2 i HIV infections newly diagnosed in injecting drug users, cases per million by country and year of diagnosis 2005–2010. EU countries, Croatia, Turkey and Norway: five highest countries in peak value 2005-2010 /stats12/inffig2a inffig2a Table-INF-g02-parti.xml
Figure INF inffig2 2 ii HIV infections newly diagnosed in injecting drug users, cases per million by country and year of diagnosis 2005–2010. EU countries, Croatia, Turkey and Norway: countries with 5 to 10 cases per million population in peak value 2005-2010 /stats12/inffig2b inffig2b Table-INF-g02-partii.xml
Figure INF inffig2 2 iii HIV infections newly diagnosed in injecting drug users, cases per million by country and year of diagnosis 2005–2010. Non-EU countries of WHO European region with over 50 cases per million population in peak value 2005-2010 /stats12/inffig2c inffig2c Table-INF-g02-partiii.xml
Figure INF inffig2 2 iv HIV infections newly diagnosed in injecting drug users, cases per million by country and year of diagnosis 2005–2010. Non-EU countries of WHO European region with 10 to 50 cases per million population in peak value 2005-2010 /stats12/inffig2d inffig2d Table-INF-g02-partiv.xml
Figure INF inffig3 3 i HIV prevalence among injecting drug users — studies with national and subnational coverage All injecting drug users, 2009 to 2010 /stats12/inffig3a inffig3a Table-DRD-g03-partii.xml
Figure INF inffig3 3 ii HIV prevalence among injecting drug users — studies with national and subnational coverage Young injecting drug users (under age 25), 2009 to 2010 /stats12/inffig3b inffig3b Table-DRD-g03-partii.xml
Figure INF inffig3 3 iii HIV prevalence among injecting drug users — studies with national and subnational coverage New injecting drug users (injecting less than 2 years), 2009 to 2010 /stats12/inffig3c inffig3c Table-DRD-g03-partii.xml
Figure INF inffig6 6 i HCV antibody prevalence among injecting drug users - studies with national and subnational coverage All injecting drug users, 2009 to 2010 /stats12/inffig6a inffig6a Table-INF-g06-parti.xml
Figure INF inffig6 6 ii HCV antibody prevalence among injecting drug users - studies with national and subnational coverage Young injecting drug users (under age 25), 2009 to 2010 /stats12/inffig6b inffig6b Table-INF-g06-parti.xml
Figure INF inffig6 6 iii HCV antibody prevalence among injecting drug users - studies with national and subnational coverage New injecting drug users (injecting less than 2 years), 2009 to 2010 /stats12/inffig6c inffig6c Table-INF-g06-parti.xml
Figure INF inffig9 9 i Prevalence of markers of HBV infection among injecting drug users — studies with national and subnational coverage Percentage ever infected (positive for aHBc), 2009 to 2010 /stats12/inffig9a inffig9a Table-INF-g09-parti.xml
Figure INF inffig9 9 ii Prevalence of markers of HBV infection among injecting drug users - studies with national and subnational coverage Percentage with current infection (positive for HBsAg), 2009 to 2010 /stats12/inffig9b inffig9b Table-INF-g09-partii.xml
Table PDU pdutab0 0   Estimates of prevalence of problem drug use at national and subnational level: bibliographic references   /stats12/pdutab0 pdutab0 Table-PDU-00-part0.xml
Table PDU pdutab1 1 i Estimates of prevalence of problem drug use at national level: Summary Table, 2005–2010, rate per 1000 aged 15–64 Overall problem drug use /stats12/pdutab1a pdutab1a Table-PDU-01-parti.xml
Table PDU pdutab1 1 ii Estimates of prevalence of problem drug use at national level: Summary Table, 2005-2010, rate per 1000 aged 15–64 Injecting drug use /stats12/pdutab1b pdutab1b Table-PDU-01-partii.xml
Table PDU pdutab1 1 iii Estimates of prevalence of problem drug use at national level: Summary Table, 2005-2010, rate per 1000 aged 15-64 Problem opioid use /stats12/pdutab1c pdutab1c Table-PDU-01-partiii.xml
Table PDU pdutab6 6 i Estimated trends in the prevalence of problem and injecting drug use - 2005 to 2010 (rate per 1 000 population aged 15 to 64): Combined estimates per country Estimated trends of overall problem drug use /stats12/pdutab6a pdutab6a Table-PDU-06-parti.xml
Table PDU pdutab6 6 ii Estimated trends in the prevalence of problem and injecting drug use — 2005 to 2010 (rate per 1 000 population aged 15 to 64): Combined estimates per country Estimated trends of problem opioid use /stats12/pdutab6b pdutab6b Table-PDU-06-partii.xml
Table PDU pdutab6 6 iii Estimated trends in the prevalence of problem and injecting drug use — 2005 to 2010 (rate per 1000 population aged 15 to 64): Combined estimates per country Estimated trends of injecting drug use /stats12/pdutab6c pdutab6c Table-PDU-06-partiii.xml
Table PDU pdutab6 6 iv Estimated trends in the prevalence of problem and injecting drug use — 2005 to 2010 (rate per 1000 population aged 15 to 64): Combined estimates per country Estimated trends of problem stimulant use /stats12/pdutab6d pdutab6d Table-PDU-06-partiv.xml
Table PDU pdutab102 102 i Prevalence of problem drug use at national level - full listing of studies Problem drug use /stats12/pdutab102a pdutab102a Table-PDU-102-parti.xml
Table PDU pdutab102 102 ii Prevalence of problem drug use at national level - full listing of studies Injecting drug use /stats12/pdutab102b pdutab102b Table-PDU-102-partii.xml
Table PDU pdutab103 103 i Prevalence of problem drug use at subnational level - full list of studies Problem drug users /stats12/pdutab103a pdutab103a Table-PDU-103-parti.xml
Table PDU pdutab103 103 ii Prevalence of problem drug use at subnational level - full list of studies Injecting drug users /stats12/pdutab103b pdutab103b Table-PDU-103-partii.xml
Table PDU pdutab104 104   Trends in injecting drug use - percentage currently injecting among all clients entering treatment for primary drug heroin, 2005 to 2010   /stats12/pdutab104 pdutab104 Table-PDU-104-part0.xml
Figure PDU pdufig1 1 i Estimates of the prevalence of problem drug use (rate per 1 000 population aged 15 to 64), studies from 2005 to 2010 - last study available Estimates of overall problem drug use /stats12/pdufig1a pdufig1a Table-PDU-g01-parti.xml
Figure PDU pdufig1 1 ii Estimates of the prevalence of problem drug use (rate per 1 000 population aged 15 to 64), 2005 to 2010 — last study available Estimates of problem opioid use /stats12/pdufig1b pdufig1b Table-PDU-g01-partii.xml
Figure PDU pdufig2 2   Estimates of the prevalence of injecting drug use (rate per 1000 population aged 15 to 64), 2005 to 2010 — last study available   /stats12/pdufig2 pdufig2 Table-PDU-g02-part0.xml
Table PPP ppptab1 1 i Price of cannabis products at retail level, 2010 Minimum, maximum, mean, median and modal price in euros /stats12/ppptab1a ppptab1a Table-PPP-01-parti.xml
Table PPP ppptab1 1 ii Price of cannabis products at retail level, 2010 Sources of information /stats12/ppptab1b ppptab1b Table-PPP-01-partii.xml
Table PPP ppptab1 1 iii Price of cannabis products at retail level, 2010 Geographical coverage / Methodology /stats12/ppptab1c ppptab1c Table-PPP-01-partiii.xml
Table PPP ppptab2 2 i Price of heroin at retail level, 2010 Minimum, maximum, mean, median and modal price in euros /stats12/ppptab2a ppptab2a Table-PPP-02-parti.xml
Table PPP ppptab2 2 ii Price of heroin at retail level, 2010 Sources of information /stats12/ppptab2b ppptab2b Table-PPP-02-partii.xml
Table PPP ppptab2 2 iii Price of heroin at retail level, 2010 Geographical coverage / Methodology /stats12/ppptab2c ppptab2c Table-PPP-02-partiii.xml
Table PPP ppptab3 3 i Price of cocaine products at retail level, 2010 Minimum, maximum, mean, median and modal price in euros /stats12/ppptab3a ppptab3a Table-PPP-03-parti.xml
Table PPP ppptab3 3 ii Price of cocaine products at retail level, 2010 Sources of information /stats12/ppptab3b ppptab3b Table-PPP-03-partii.xml
Table PPP ppptab3 3 iii Price of cocaine products at retail level, 2010 Geographical coverage / Methodology /stats12/ppptab3c ppptab3c Table-PPP-03-partiii.xml
Table PPP ppptab4 4 i Price of synthetic drugs at retail level, 2010 Minimum, maximum, mean, median and modal price in euros /stats12/ppptab4a ppptab4a Table-PPP-04-parti.xml
Table PPP ppptab4 4 ii Price of synthetic drugs at retail level, 2010 Sources of information /stats12/ppptab4b ppptab4b Table-PPP-04-partii.xml
Table PPP ppptab4 4 iii Price of synthetic drugs at retail level, 2010 Geographical coverage / Methodology /stats12/ppptab4c ppptab4c Table-PPP-04-partiii.xml
Table PPP ppptab5 5 i Potency of cannabis products at retail level, 2010 Minimum, maximum, mean, median and modal potency recorded, measured as percentage of THC content /stats12/ppptab5a ppptab5a Table-PPP-05-parti.xml
Table PPP ppptab5 5 ii Potency of cannabis products at retail level, 2010 Sources of information /stats12/ppptab5b ppptab5b Table-PPP-05-partii.xml
Table PPP ppptab5 5 iii Potency of cannabis products at retail level, 2010 Geographical coverage / Sampling frame / Type of study /stats12/ppptab5c ppptab5c Table-PPP-05-partiii.xml
Table PPP ppptab6 6 i Purity of heroin at retail level, 2010 Minimum, maximum, mean, median and modal purity recorded (percentage) /stats12/ppptab6a ppptab6a Table-PPP-06-parti.xml
Table PPP ppptab6 6 ii Purity of heroin at retail level, 2010 Sources of information /stats12/ppptab6b ppptab6b Table-PPP-06-partii.xml
Table PPP ppptab6 6 iii Purity of heroin at retail level, 2010 Geographical coverage / Sampling frame / Type of study / Purity determined to base~salt /stats12/ppptab6c ppptab6c Table-PPP-06-partiii.xml
Table PPP ppptab7 7 i Purity of cocaine products at retail level, 2010 Minimum, maximum, mean, median and modal purity recorded (percentage) /stats12/ppptab7a ppptab7a Table-PPP-07-parti.xml
Table PPP ppptab7 7 ii Purity of cocaine products at retail level, 2010 Sources of information /stats12/ppptab7b ppptab7b Table-PPP-07-partii.xml
Table PPP ppptab7 7 iii Purity of cocaine products at retail level, 2010 Geographical coverage / Sampling frame / Type of study / Purity determined to base~salt /stats12/ppptab7c ppptab7c Table-PPP-07-partiii.xml
Table PPP ppptab8 8 i Purity of synthetic drugs at retail level, 2010 Minimum, maximum, mean, median and modal purity recorded /stats12/ppptab8a ppptab8a Table-PPP-08-parti.xml
Table PPP ppptab8 8 ii Purity of synthetic drugs at retail level, 2010 Sources of information /stats12/ppptab8b ppptab8b Table-PPP-08-partii.xml
Table PPP ppptab8 8 iii Purity of synthetic drugs at retail level, 2010 Geographical coverage / Sampling frame / Type of study /stats12/ppptab8c ppptab8c Table-PPP-08-partiii.xml
Table PPP ppptab9 9 i Composition of illicit drug tablets, 2010 Content of synthetic scheduled illicit drugs /stats12/ppptab9a ppptab9a Table-PPP-09-parti.xml
Table PPP ppptab9 9 ii Composition of illicit drug tablets, 2010 Sources of information /stats12/ppptab9b ppptab9b Table-PPP-09-partii.xml
Table PPP ppptab9 9 iii Composition of illicit drug tablets, 2010 Sampling frame / Type of monitoring system /stats12/ppptab9c ppptab9c Table-PPP-09-partiii.xml
Table PPP ppptab9 9 iv Composition of illicit drug tablets, 2010 Information available on substances listed in categories 'Miscellaneous' and 'Other' /stats12/ppptab9d ppptab9d Table-PPP-09-partiv.xml
Table PPP ppptab9 9 v Composition of illicit drug tablets, 2010 Information available on adulterants, cutting agents and/or impurities. /stats12/ppptab9e ppptab9e Table-PPP-09-partv.xml
Figure PPP pppfig1 1   Indexed trends in EU retail prices for major drug types, adjusting for inflation, 2005–10   /stats12/pppfig1 pppfig1 Table-PPP-01-parti.xml
Figure PPP pppfig2 2   Indexed trends in EU potency/purity for major drug types, adjusting for population size, 2005-2010   /stats12/pppfig2 pppfig2 Table-PPP-02-parti.xml
Table SZR szrtab0 0 i Seizures of illicit drugs Data source: name of institution and name of monitoring system/study /stats12/szrtab0a szrtab0a Table-SZR-00-parti.xml
Table SZR szrtab0 0 ii Seizures of illicit drugs Methodological comments /stats12/szrtab0b szrtab0b Table-SZR-00-partii.xml
Table SZR szrtab1 1   Number of cannabis resin seizures, 1995 to 2010   /stats12/szrtab1 szrtab1 Table-SZR-01-parti.xml
Table SZR szrtab2 2   Quantities (kg) of cannabis resin seized, 1995 to 2010   /stats12/szrtab2 szrtab2 Table-SZR-02-parti.xml
Table SZR szrtab3 3   Number of herbal cannabis seizures, 1995 to 2010   /stats12/szrtab3 szrtab3 Table-SZR-03-parti.xml
Table SZR szrtab4 4   Quantities (kg) of herbal cannabis seized, 1995 to 2010   /stats12/szrtab4 szrtab4 Table-SZR-04-parti.xml
Table SZR szrtab5 5   Number of seizures of cannabis plants, 1995 to 2010   /stats12/szrtab5 szrtab5 Table-SZR-05-parti.xml
Table SZR szrtab6 6 i Quantities (number of plants) of cannabis plants seized, 1995 to 2010 Number of plants, 1995 to 2010 /stats12/szrtab6a szrtab6a Table-SZR-06-parti.xml
Table SZR szrtab6 6 ii Quantities (Kg) of cannabis plants seized, 1995 to 2010 Quantity (Kg) of plants, 1995 to 2010 /stats12/szrtab6b szrtab6b Table-SZR-06-partii.xml
Table SZR szrtab7 7 i Number of heroin seizures 1995 to 2010 1995 to 2010 /stats12/szrtab7a szrtab7a Table-SZR-07-parti.xml
Table SZR szrtab8 8 i Quantities (kg) of heroin seized 1995 to 2010 1995 to 2010 /stats12/szrtab8a szrtab8a Table-SZR-08-parti.xml
Table SZR szrtab9 9 i Number of cocaine seizures 1995 to 2010 1995 to 2010 /stats12/szrtab9a szrtab9a Table-SZR-09-parti.xml
Table SZR szrtab10 10 i Quantities (kg) of cocaine seized 1995 to 2010 1995 to 2010 /stats12/szrtab10a szrtab10a Table-SZR-10-parti.xml
Table SZR szrtab11 11 i Number of amphetamine seizures 1995 to 2010 1995 to 2010 /stats12/szrtab11a szrtab11a Table-SZR-11-parti.xml
Table SZR szrtab12 12 i Quantities (kg) of amphetamine seized 1995 to 2010 Quantities (kg) of amphetamine, 1995 to 2010 /stats12/szrtab12a szrtab12a Table-SZR-12-parti.xml
Table SZR szrtab12 12 iii Quantities (tablets) of amphetamine seized 1995 to 2010 Quantity (tablets) of amphetamine, 1995 to 2010 /stats12/szrtab12c szrtab12c Table-SZR-12-partiii.xml
Table SZR szrtab13 13 i Number of ecstasy seizures 1995 to 2010 1995 to 2010 /stats12/szrtab13a szrtab13a Table-SZR-13-parti.xml
Table SZR szrtab14 14 i Quantities (tablets) of ecstasy seized 1995 to 2010 Quantity (tablets) of ecstasy, 1995 to 2010 /stats12/szrtab14a szrtab14a Table-SZR-14-parti.xml
Table SZR szrtab14 14 ii Quantities (Kg) of ecstasy seized 1995 to 2010 Quantity (Kg) of ecstasy, 1995 to 2010 /stats12/szrtab14b szrtab14b Table-SZR-14-partiii.xml
Table SZR szrtab15 15   Number of LSD seizures 1995 to 2010 1995 to 2010 /stats12/szrtab15 szrtab15 Table-SZR-15-parti.xml
Table SZR szrtab16 16   Quantities (units) of LSD seized 1995 to 2010 1995 to 2010 /stats12/szrtab16 szrtab16 Table-SZR-16-parti.xml
Table SZR szrtab17 17   Number of methamphetamine seizures, 2001 to 2010   /stats12/szrtab17 szrtab17 Table-SZR-17-parti.xml
Table SZR szrtab18 18   Quantities (kg) of Methamphetamine seized 2001 to 2010   /stats12/szrtab18 szrtab18 Table-SZR-18-parti.xml
Table SZR szrtab19 19   Number of crack cocaine seizures, 1995-2010   /stats12/szrtab19 szrtab19 Table-SZR-19-parti.xml
Table SZR szrtab20 20   Quantities (kg) of crack cocaine seized 1995 to 2010   /stats12/szrtab20 szrtab20 Table-SZR-20-parti.xml
Table SZR szrtab21 21 i Other substances seized, 2004 to 2010 Other substances siezed not included in other SZR tables, 2004 to 2010 /stats12/szrtab21a szrtab21a Table-SZR-21-parti.xml
Figure SZR szrfig1 1   Estimated number of heroin seizures and quantities seized (kg) in the EU, Croatia, Turkey and Norway, 2005-2010.   /stats12/szrfig1 szrfig1 Table-SZR-01-parti.xml
Figure SZR szrfig2 2   Estimated number of cocaine seizures and quantities seized (kg) in the EU, Croatia, Turkey and Norway, 2005-2010.   /stats12/szrfig2 szrfig2 Table-SZR-02-parti.xml
Table TDI tditab1 1   Clients entering treatment and treatment units by country, 2010 or most recent year available   /stats12/tditab1 tditab1 Table-TDI-01-part0.xml
Table TDI tditab2 2 i Clients entering treatment and reporting treatment units, 1998 to 2010 New clients by country and year of treatment /stats12/tditab2a tditab2a Table-TDI-02-parti.xml
Table TDI tditab2 2 ii Clients entering treatment and reporting treatment units, 1998 to 2010 All clients by country and year of treatment /stats12/tditab2b tditab2b Table-TDI-02-partii.xml
Table TDI tditab2 2 iii Clients entering treatment and reporting treatment units, 1998 to 2010 Reporting treatment units by country and year of treatment /stats12/tditab2c tditab2c Table-TDI-02-partiii.xml
Table TDI tditab2 2 iv Clients entering treatment and reporting treatment units, 1998 to 2010 Types of reporting treatment unit by country /stats12/tditab2d tditab2d Table-TDI-02-partiv.xml
Table TDI tditab3 3 i New clients entering treatment by primary drug, 1998 to 2010 New heroin clients by country and year of treatment (%) /stats12/tditab3a tditab3a Table-TDI-03-parti.xml
Table TDI tditab3 3 ii New clients entering treatment by primary drug, 1998 to 2010 New cocaine clients by country and year of treatment (%) /stats12/tditab3b tditab3b Table-TDI-03-partii.xml
Table TDI tditab3 3 iii New clients entering treatment by primary drug, 1998 to 2010 New stimulants (amphetamines and MDMA) clients by country and year of treatment (%) /stats12/tditab3c tditab3c Table-TDI-03-partiii.xml
Table TDI tditab3 3 iv New clients entering treatment by primary drug, 1998 to 2010 New cannabis clients by country and year of treatment (%) /stats12/tditab3d tditab3d Table-TDI-03-partiv.xml
Table TDI tditab4 4 i Demographic characteristics of clients entering treatment, 2010 or most recent year available New clients by country and gender (%) /stats12/tditab4a tditab4a Table-TDI-04-parti.xml
Table TDI tditab4 4 ii Demographic characteristics of clients entering treatment, 2010 or most recent year available All clients by country and gender (%) /stats12/tditab4b tditab4b Table-TDI-04-partii.xml
Table TDI tditab4 4 iii Demographic characteristics of clients entering treatment, 2010 or most recent year available New clients by country and age (%) /stats12/tditab4c tditab4c Table-TDI-04-partiii.xml
Table TDI tditab4 4 iv Demographic characteristics of clients entering treatment, 2010 or most recent year available All clients by country and age (%) /stats12/tditab4d tditab4d Table-TDI-04-partiv.xml
Table TDI tditab5 5 i Primary drug and rates of injection of primary drug of clients entering treatment, 2010 or most recent year available New clients by country and primary drug (%), regardless whether they inject the drug /stats12/tditab5a tditab5a Table-TDI-05-parti.xml
Table TDI tditab5 5 ii Primary drug and rates of injection of primary drug of clients entering treatment, 2010 or most recent year available All clients by country and primary drug (%), regardless whether they inject the drug /stats12/tditab5b tditab5b Table-TDI-05-partii.xml
Table TDI tditab5 5 iii Primary drug and rates of injection of primary drug of clients entering treatment, 2010 or most recent year available New clients by country and rates of injection of primary drug (%) /stats12/tditab5c tditab5c Table-TDI-05-partiii.xml
Table TDI tditab5 5 iv Primary drug and rates of injection of primary drug of clients entering treatment, 2010 or most recent year available All clients by country and rates of injection of primary drug (%) /stats12/tditab5d tditab5d Table-TDI-05-partiv.xml
Table TDI tditab6 6   Incidence of treatment demand for drug use, 2010 or most recent year available. New clients by country (rate per 100 000 population aged 15 to 64 years old)   /stats12/tditab6 tditab6 Table-TDI-06-part0.xml
Table TDI tditab7 7 i Data coverage, 2010 or most recent year available Clients entering treatment by country and type of treatment centre and type of client /stats12/tditab7a tditab7a Table-TDI-07-parti.xml
Table TDI tditab7 7 ii Data coverage, 2010 or most recent year available Units by country and type of treatment centre and reporting status /stats12/tditab7b tditab7b Table-TDI-07-partii.xml
Table TDI tditab8 8 i Primary use of stimulants of clients entering treatment, 2010 or most recent year available New clients by country and type of stimulant (%) /stats12/tditab8a tditab8a Table-TDI-08-parti.xml
Table TDI tditab8 8 ii Primary use of stimulants of clients entering treatment, 2010 or most recent year available All clients by country and type of stimulant (%) /stats12/tditab8b tditab8b Table-TDI-08-partii.xml
Table TDI tditab9 9 i Demographic characteristics of clients entering outpatient treatment, 2010 or most recent year available New outpatient clients by country and gender /stats12/tditab9a tditab9a Table-TDI-09-parti.xml
Table TDI tditab9 9 ii Demographic characteristics of clients entering outpatient treatment, 2010 or most recent year available All outpatient clients by country and gender /stats12/tditab9b tditab9b Table-TDI-09-partii.xml
Table TDI tditab9 9 iii Demographic characteristics of clients entering outpatient treatment, 2010 or most recent year available New outpatient clients by country and age /stats12/tditab9c tditab9c Table-TDI-09-partiii.xml
Table TDI tditab9 9 iv Demographic characteristics of clients entering outpatient treatment, 2010 or most recent year available All outpatient clients by country and age /stats12/tditab9d tditab9d Table-TDI-09-partiv.xml
Table TDI tditab10 10 i Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available New outpatient clients, age distribution by primary drug (%) /stats12/tditab10a tditab10a Table-TDI-10-parti.xml
Table TDI tditab10 10 ii Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available New outpatient clients, primary drug distribution by age (%) /stats12/tditab10b tditab10b Table-TDI-10-partii.xml
Table TDI tditab10 10 iii Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available All outpatient clients, age distribution by primary drug (%) /stats12/tditab10c tditab10c Table-TDI-10-partiii.xml
Table TDI tditab10 10 iv Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available All outpatient clients, primary drug distribution by age (%) /stats12/tditab10d tditab10d Table-TDI-10-partiv.xml
Table TDI tditab10 10 v Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available New inpatient clients, age distribution by primary drug (%) /stats12/tditab10e tditab10e Table-TDI-10-partv.xml
Table TDI tditab10 10 vi Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available New inpatient clients, primary drug distribution by age (%) /stats12/tditab10f tditab10f Table-TDI-10-partvi.xml
Table TDI tditab10 10 vii Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available All inpatient clients, age distribution by primary drug (%) /stats12/tditab10g tditab10g Table-TDI-10-partvii.xml
Table TDI tditab10 10 viii Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available All inpatient clients, primary drug distribution by age (%) /stats12/tditab10h tditab10h Table-TDI-10-partviii.xml
Table TDI tditab11 11 i Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available New outpatient clients, age at first use distribution by primary drug (%) /stats12/tditab11a tditab11a Table-TDI-11-parti.xml
Table TDI tditab11 11 ii Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available New outpatient clients, primary drug distribution by age at first use (%) /stats12/tditab11b tditab11b Table-TDI-11-partii.xml
Table TDI tditab11 11 iii Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available All outpatient clients, age at first use distribution by primary drug (%) /stats12/tditab11c tditab11c Table-TDI-11-partiii.xml
Table TDI tditab11 11 iv Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available All outpatient clients, primary drug distribution by age at first use (%) /stats12/tditab11d tditab11d Table-TDI-11-partiv.xml
Table TDI tditab11 11 v Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available New inpatient clients, age at first use distribution by primary drug (%) /stats12/tditab11e tditab11e Table-TDI-11-partv.xml
Table TDI tditab11 11 vi Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available New inpatient clients, primary drug distribution by age at first use (%) /stats12/tditab11f tditab11f Table-TDI-11-partvi.xml
Table TDI tditab11 11 vii Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available All inpatient clients, age at first use distribution by primary drug (%) /stats12/tditab11g tditab11g Table-TDI-11-partvii.xml
Table TDI tditab11 11 viii Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available All inpatient clients, primary drug distribution by age at first use (%) /stats12/tditab11h tditab11h Table-TDI-11-partviii.xml
Table TDI tditab12 12 i Education status of clients entering treatment, 2010 or most recent year available New outpatient clients by country and education status (%) /stats12/tditab12a tditab12a Table-TDI-12-parti.xml
Table TDI tditab12 12 ii Education status of clients entering treatment, 2010 or most recent year available All outpatient clients by country and education status (%) /stats12/tditab12b tditab12b Table-TDI-12-partii.xml
Table TDI tditab12 12 iii Education status of clients entering treatment, 2010 or most recent year available New inpatient clients by country and education status (%) /stats12/tditab12c tditab12c Table-TDI-12-partiii.xml
Table TDI tditab12 12 iv Education status of clients entering treatment, 2010 or most recent year available All inpatient clients by country and education status (%) /stats12/tditab12d tditab12d Table-TDI-12-partiv.xml
Table TDI tditab13 13 i Labour status of clients entering treatment, 2010 or most recent year available New outpatient clients by country and labour status (%) /stats12/tditab13a tditab13a Table-TDI-13-parti.xml
Table TDI tditab13 13 ii Labour status of clients entering treatment, 2010 or most recent year available All outpatient clients by country and labour status (%) /stats12/tditab13b tditab13b Table-TDI-13-partii.xml
Table TDI tditab13 13 iii Labour status of clients entering treatment, 2010 or most recent year available New inpatient clients by country and labour status (%) /stats12/tditab13c tditab13c Table-TDI-13-partiii.xml
Table TDI tditab13 13 iv Labour status of clients entering treatment, 2010 or most recent year available All inpatient clients by country and labour status (%) /stats12/tditab13d tditab13d Table-TDI-13-partiv.xml
Table TDI tditab14 14 i Persons with whom client is living on entering treatment, 2010 or most recent year available New outpatient clients by country and with whom living (%) /stats12/tditab14a tditab14a Table-TDI-14-parti.xml
Table TDI tditab14 14 ii Persons with whom client is living on entering treatment, 2010 or most recent year available All outpatient clients by country and with whom living (%) /stats12/tditab14b tditab14b Table-TDI-14-partii.xml
Table TDI tditab14 14 iii Persons with whom client is living on entering treatment, 2010 or most recent year available New inpatient clients by country and with whom living (%) /stats12/tditab14c tditab14c Table-TDI-14-partiii.xml
Table TDI tditab14 14 iv Persons with whom client is living on entering treatment, 2010 or most recent year available All inpatient clients by country and with whom living (%) /stats12/tditab14d tditab14d Table-TDI-14-partiv.xml
Table TDI tditab15 15 i Type of accommodation of clients entering treatment, 2010 or most recent year available New clients entering outpatient treatment by country and type of accommodation (%) /stats12/tditab15a tditab15a Table-TDI-15-parti.xml
Table TDI tditab15 15 ii Type of accommodation of clients entering treatment, 2010 or most recent year available All clients entering outpatient treatment by country and type of accommodation (%) /stats12/tditab15b tditab15b Table-TDI-15-partii.xml
Table TDI tditab15 15 iii Type of accommodation of clients entering treatment, 2010 or most recent year available New clients entering inpatient treatment by country and type of accommodation (%) /stats12/tditab15c tditab15c Table-TDI-15-partiii.xml
Table TDI tditab15 15 iv Type of accommodation of clients entering treatment, 2010 or most recent year available All clients entering inpatient treatment by country and type of accommodation (%) /stats12/tditab15d tditab15d Table-TDI-15-partiv.xml
Table TDI tditab16 16 i Source of referral of clients entering treatment, 2010 or most recent year available New outpatient clients by country and source of referral (%) /stats12/tditab16a tditab16a Table-TDI-16-parti.xml
Table TDI tditab16 16 ii Source of referral of clients entering treatment, 2010 or most recent year available All outpatient clients by country and source of referral (%) /stats12/tditab16b tditab16b Table-TDI-16-partii.xml
Table TDI tditab16 16 iii Source of referral of clients entering treatment, 2010 or most recent year available New inpatient clients by country and source of referral (%) /stats12/tditab16c tditab16c Table-TDI-16-partiii.xml
Table TDI tditab16 16 iv Source of referral of clients entering treatment, 2010 or most recent year available All inpatient clients by country and source of referral (%) /stats12/tditab16d tditab16d Table-TDI-16-partiv.xml
Table TDI tditab17 17 i Route of administration by primary drug of clients entering treatment, 2010 or most recent year available New opioid outpatient clients by country and usual route of administration (%) /stats12/tditab17a tditab17a Table-TDI-17-parti.xml
Table TDI tditab17 17 ii Route of administration by primary drug of clients entering treatment, 2010 or most recent year available All opioid outpatient clients by country and usual route of administration (%) /stats12/tditab17b tditab17b Table-TDI-17-partii.xml
Table TDI tditab17 17 iii Route of administration by primary drug of clients entering treatment, 2010 or most recent year available New cocaine (HCl and crack) outpatient clients by country and usual route of administration (%) /stats12/tditab17c tditab17c Table-TDI-17-partiii.xml
Table TDI tditab17 17 iv Route of administration by primary drug of clients entering treatment, 2010 or most recent year available All cocaine (HCl and crack) outpatient clients by country and usual route of administration (%) /stats12/tditab17d tditab17d Table-TDI-17-partiv.xml
Table TDI tditab17 17 ix Route of administration by primary drug of clients entering treatment, 2010 or most recent year available New cannabis outpatient clients by country and usual route of administration (%) /stats12/tditab17i tditab17i Table-TDI-17-partix.xml
Table TDI tditab17 17 v Route of administration by primary drug of clients entering treatment, 2010 or most recent year available New stimulants (other than cocaine) outpatient clients by country and usual route of administration (%) /stats12/tditab17e tditab17e Table-TDI-17-partv.xml
Table TDI tditab17 17 vi Route of administration by primary drug of clients entering treatment, 2010 or most recent year available All stimulants (other than cocaine) outpatient clients by country and usual route of administration (%) /stats12/tditab17f tditab17f Table-TDI-17-partvi.xml
Table TDI tditab17 17 vii Route of administration by primary drug of clients entering treatment, 2010 or most recent year available New hypnotics and sedatives outpatient clients by country and usual route of administration (%) /stats12/tditab17g tditab17g Table-TDI-17-partvii.xml
Table TDI tditab17 17 viii Route of administration by primary drug of clients entering treatment, 2010 or most recent year available All hypnotics and sedatives outpatient clients by country and usual route of administration (%) /stats12/tditab17h tditab17h Table-TDI-17-partviii.xml
Table TDI tditab17 17 x Route of administration by primary drug of clients entering treatment, 2010 or most recent year available All cannabis outpatient clients by country and usual route of administration (%) /stats12/tditab17j tditab17j Table-TDI-17-partx.xml
Table TDI tditab18 18 i Frequency of use of primary drug of clients entering treatment, 2010 or most recent year available New outpatient clients by primary drug and frequency of use (%) /stats12/tditab18a tditab18a Table-TDI-18-parti.xml
Table TDI tditab18 18 ii Frequency of use of primary drug of clients entering treatment, 2010 or most recent year available All outpatient clients by primary drug and frequency of use (%) /stats12/tditab18b tditab18b Table-TDI-18-partii.xml
Table TDI tditab18 18 iii Frequency of use of primary drug of clients entering treatment, 2010 or most recent year available New inpatient clients by primary drug and frequency of use (%) /stats12/tditab18c tditab18c Table-TDI-18-partiii.xml
Table TDI tditab18 18 iv Frequency of use of primary drug of clients entering treatment, 2010 or most recent year available All inpatient clients by primary drug and frequency of use (%) /stats12/tditab18d tditab18d Table-TDI-18-partiv.xml
Table TDI tditab19 19 i Primary drug of clients entering treatment, 2010 or most recent year available New outpatient clients by country and primary drug (%) /stats12/tditab19a tditab19a Table-TDI-19-parti.xml
Table TDI tditab19 19 ii Primary drug of clients entering treatment, 2010 or most recent year available All outpatient clients by country and primary drug (%) /stats12/tditab19b tditab19b Table-TDI-19-partii.xml
Table TDI tditab19 19 iii Primary drug of clients entering treatment, 2010 or most recent year available New inpatient clients by country and primary drug (%) /stats12/tditab19c tditab19c Table-TDI-19-partiii.xml
Table TDI tditab19 19 iv Primary drug of clients entering treatment, 2010 or most recent year available All inpatient clients by country and primary drug (%) /stats12/tditab19d tditab19d Table-TDI-19-partiv.xml
Table TDI tditab21 21 i Gender ratio by primary drug of clients entering treatment, 2010 or most recent year available New outpatient clients, ratio of males to females by country and primary drug /stats12/tditab21a tditab21a Table-TDI-21-parti.xml
Table TDI tditab21 21 ii Gender ratio by primary drug of clients entering treatment, 2010 or most recent year available All outpatient clients, ratio of males to females by country and primary drug /stats12/tditab21b tditab21b Table-TDI-21-partii.xml
Table TDI tditab21 21 iii Gender ratio by primary drug of clients entering treatment, 2010 or most recent year available New inpatient clients, ratio of males to females by country and primary drug /stats12/tditab21c tditab21c Table-TDI-21-partiii.xml
Table TDI tditab21 21 iv Gender ratio by primary drug of clients entering treatment, 2010 or most recent year available All inpatient clients, ratio of males to females by country and primary drug /stats12/tditab21d tditab21d Table-TDI-21-partiv.xml
Table TDI tditab22 22 i Secondary drugs cited by clients entering treatment, 2010 or most recent year available Outpatient units /stats12/tditab22a tditab22a Table-TDI-22-parti.xml
Table TDI tditab22 22 ii Secondary drugs cited by clients entering treatment, 2010 or most recent year available Inpatient units /stats12/tditab22b tditab22b Table-TDI-22-partii.xml
Table TDI tditab24 24 i Type of treatment centre by primary drug of clients entering treatment, 2010 or most recent year available New clients by country and primary drug and type of treatment centre (%) /stats12/tditab24a tditab24a Table-TDI-24-parti.xml
Table TDI tditab24 24 ii Type of treatment centre by primary drug of clients entering treatment, 2010 or most recent year available All clients by country and primary drug and type of treatment centre (%) /stats12/tditab24b tditab24b Table-TDI-24-partii.xml
Table TDI tditab25 25   Age distribution of all clients entering outpatient treatment by primary drug and gender, 2010 or most recent year available   /stats12/tditab25 tditab25 Table-TDI-25-part0.xml
Table TDI tditab32 32 i Mean age of clients entering treatment by primary drug and gender, 2010 or most recent year available Outpatient clients /stats12/tditab32a tditab32a Table-TDI-32-parti.xml
Table TDI tditab32 32 ii Mean age of clients entering treatment by primary drug and gender, 2010 or most recent year available Inpatient clients /stats12/tditab32b tditab32b Table-TDI-32-partii.xml
Table TDI tditab33 33 i Mean age at first use and mean age at entering treatment by gender and primary drug among new clients entering treatment, 2010 or most recent year available Outpatient units /stats12/tditab33a tditab33a Table-TDI-33-parti.xml
Table TDI tditab33 33 ii Mean age at first use and mean age at entering treatment by gender and primary drug among new clients entering treatment, 2010 or most recent year available Inpatient units /stats12/tditab33b tditab33b Table-TDI-33-partii.xml
Table TDI tditab36 36   Primary amphetamine use among new clients entering treatment (%), 2005 to 2010   /stats12/tditab36 tditab36 Table-TDI-36-part0.xml
Table TDI tditab37 37 i Amphetamines and ecstasy clients entering drug treatment, 2010 or most recent year available All clients by country and primary drug and type of treatment unit /stats12/tditab37a tditab37a Table-TDI-37-parti.xml
Table TDI tditab37 37 ii Amphetamines and ecstasy clients entering drug treatment, 2010 or most recent year available Outpatient clients by primary drug and mean age, gender ratio /stats12/tditab37b tditab37b Table-TDI-37-partii.xml
Table TDI tditab37 37 iii Amphetamines and ecstasy clients entering drug treatment, 2010 or most recent year available Inpatient clients by primary drug and mean age, gender ratio /stats12/tditab37c tditab37c Table-TDI-37-partiii.xml
Table TDI tditab37 37 iv Amphetamines and ecstasy clients entering drug treatment, 2010 or most recent year available Outpatient clients by secondary drug and primary drug /stats12/tditab37d tditab37d Table-TDI-37-partiv.xml
Table TDI tditab37 37 v Amphetamines and ecstasy clients entering drug treatment, 2010 or most recent year available Inpatient clients by secondary drug and primary drug /stats12/tditab37e tditab37e Table-TDI-37-partv.xml
Table TDI tditab102 102 i New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available New opioid outpatient clients by country and age /stats12/tditab102a tditab102a Table-TDI-102-parti.xml
Table TDI tditab102 102 ii New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available New cocaine (HCI and 'crack') outpatient clients by country and age /stats12/tditab102b tditab102b Table-TDI-102-partii.xml
Table TDI tditab102 102 iii New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available New stimulants (other than cocaine) outpatient clients by country and age /stats12/tditab102c tditab102c Table-TDI-102-partiii.xml
Table TDI tditab102 102 iv New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available New hallucinogen outpatient clients by country and age /stats12/tditab102d tditab102d Table-TDI-102-partiv.xml
Table TDI tditab102 102 v New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available New hypnotics and sedatives outpatient clients by country and age /stats12/tditab102e tditab102e Table-TDI-102-partv.xml
Table TDI tditab102 102 vi New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available New volatile inhalant outpatient clients by country and age /stats12/tditab102f tditab102f Table-TDI-102-partvi.xml
Table TDI tditab102 102 vii New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available New cannabis outpatient clients by country and age /stats12/tditab102g tditab102g Table-TDI-102-partvii.xml
Table TDI tditab102 102 viii New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available New 'other drugs' outpatient clients by country and by age /stats12/tditab102h tditab102h Table-TDI-102-partviii.xml
Table TDI tditab103 103 i All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available All opioid outpatient clients by country and age /stats12/tditab103a tditab103a Table-TDI-103-parti.xml
Table TDI tditab103 103 ii All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available All cocaine (HCI and 'crack') outpatient clients by country and age /stats12/tditab103b tditab103b Table-TDI-103-partii.xml
Table TDI tditab103 103 iii All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available All stimulants (other than cocaine) outpatient clients by country and age /stats12/tditab103c tditab103c Table-TDI-103-partiii.xml
Table TDI tditab103 103 iv All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available All hallucinogen outpatient clients by country and age /stats12/tditab103d tditab103d Table-TDI-103-partiv.xml
Table TDI tditab103 103 v All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available All hypnotics and sedatives outpatient clients by country and age /stats12/tditab103e tditab103e Table-TDI-103-partv.xml
Table TDI tditab103 103 vi All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available All volatile inhalant outpatient clients by country and age /stats12/tditab103f tditab103f Table-TDI-103-partvi.xml
Table TDI tditab103 103 vii All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available All cannabis outpatient clients by country and age /stats12/tditab103g tditab103g Table-TDI-103-partvii.xml
Table TDI tditab103 103 viii All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available All 'other drugs' outpatient clients by country and by age /stats12/tditab103h tditab103h Table-TDI-103-partviii.xml
Table TDI tditab104 104 i New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available New opioid inpatient clients by country and age /stats12/tditab104a tditab104a Table-TDI-104-parti.xml
Table TDI tditab104 104 ii New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available New cocaine (HCI and 'crack') inpatient clients by country and age /stats12/tditab104b tditab104b Table-TDI-104-partii.xml
Table TDI tditab104 104 iii New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available New stimulants (other than cocaine) inpatient clients by country and age /stats12/tditab104c tditab104c Table-TDI-104-partiii.xml
Table TDI tditab104 104 iv New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available New hallucinogen inpatient clients by country and age /stats12/tditab104d tditab104d Table-TDI-104-partiv.xml
Table TDI tditab104 104 v New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available New hypnotics and sedatives inpatient clients by country and age /stats12/tditab104e tditab104e Table-TDI-104-partv.xml
Table TDI tditab104 104 vi New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available New volatile inhalant inpatient clients by country and age /stats12/tditab104f tditab104f Table-TDI-104-partvi.xml
Table TDI tditab104 104 vii New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available New cannabis inpatient clients by country and age /stats12/tditab104g tditab104g Table-TDI-104-partvii.xml
Table TDI tditab104 104 viii New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available New 'other drugs' inpatient clients by country and by age /stats12/tditab104h tditab104h Table-TDI-104-partviii.xml
Table TDI tditab105 105 i All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available All opioid inpatient clients by country and age /stats12/tditab105a tditab105a Table-TDI-105-parti.xml
Table TDI tditab105 105 ii All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available All cocaine (HCI and 'crack') inpatient clients by country and age /stats12/tditab105b tditab105b Table-TDI-105-partii.xml
Table TDI tditab105 105 iii All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available All stimulants (other than cocaine) inpatient clients by country and age /stats12/tditab105c tditab105c Table-TDI-105-partiii.xml
Table TDI tditab105 105 iv All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available All hallucinogen inpatient clients by country and age /stats12/tditab105d tditab105d Table-TDI-105-partiv.xml
Table TDI tditab105 105 v All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available All hypnotics and sedatives inpatient clients by country and age /stats12/tditab105e tditab105e Table-TDI-105-partv.xml
Table TDI tditab105 105 vi All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available All volatile inhalant inpatient clients by country and age /stats12/tditab105f tditab105f Table-TDI-105-partvi.xml
Table TDI tditab105 105 vii All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available All cannabis inpatient clients by country and age /stats12/tditab105g tditab105g Table-TDI-105-partvii.xml
Table TDI tditab105 105 viii All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available All 'other drugs' inpatient clients by country and by age /stats12/tditab105h tditab105h Table-TDI-105-partviii.xml
Table TDI tditab106 106 i New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available New opioid outpatient clients by country and age at first use /stats12/tditab106a tditab106a Table-TDI-106-parti.xml
Table TDI tditab106 106 ii New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available New cocaine (HCI and 'crack') outpatient clients by country and age at first use /stats12/tditab106b tditab106b Table-TDI-106-partii.xml
Table TDI tditab106 106 iii New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available New stimulants (other than cocaine) outpatient clients by country and age at first use /stats12/tditab106c tditab106c Table-TDI-106-partiii.xml
Table TDI tditab106 106 iv New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available New hallucinogen outpatient clients by country and age at first use /stats12/tditab106d tditab106d Table-TDI-106-partiv.xml
Table TDI tditab106 106 v New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available New hypnotics and sedatives outpatient clients by country and age at first use /stats12/tditab106e tditab106e Table-TDI-106-partv.xml
Table TDI tditab106 106 vi New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available New volatile inhalant outpatient clients by country and age at first use /stats12/tditab106f tditab106f Table-TDI-106-partvi.xml
Table TDI tditab106 106 vii New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available New cannabis outpatient clients by country and age at first use /stats12/tditab106g tditab106g Table-TDI-106-partvii.xml
Table TDI tditab106 106 viii New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available New 'other drugs' outpatient clients by country and by age at first use /stats12/tditab106h tditab106h Table-TDI-106-partviii.xml
Table TDI tditab107 107 i All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available All opioid outpatient clients by country and age at first use /stats12/tditab107a tditab107a Table-TDI-107-parti.xml
Table TDI tditab107 107 ii All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available All cocaine (HCI and 'crack') outpatient clients by country and age at first use /stats12/tditab107b tditab107b Table-TDI-107-partii.xml
Table TDI tditab107 107 iii All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available All stimulants (other than cocaine) outpatient clients by country and age at first use /stats12/tditab107c tditab107c Table-TDI-107-partiii.xml
Table TDI tditab107 107 iv All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available All hallucinogen outpatient clients by country and age at first use /stats12/tditab107d tditab107d Table-TDI-107-partiv.xml
Table TDI tditab107 107 v All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available All hypnotics and sedatives outpatient clients by country and age at first use /stats12/tditab107e tditab107e Table-TDI-107-partv.xml
Table TDI tditab107 107 vi All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available All volatile inhalant outpatient clients by country and age at first use /stats12/tditab107f tditab107f Table-TDI-107-partvi.xml
Table TDI tditab107 107 vii All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available All cannabis outpatient clients by country and by age at first use /stats12/tditab107g tditab107g Table-TDI-107-partvii.xml
Table TDI tditab107 107 viii All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available All 'other drugs' outpatient clients by country and by age at first use /stats12/tditab107h tditab107h Table-TDI-107-partviii.xml
Table TDI tditab108 108 i New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available New opioid inpatient clients by country and age at first use /stats12/tditab108a tditab108a Table-TDI-108-parti.xml
Table TDI tditab108 108 ii New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available New cocaine (HCI and 'crack') inpatient clients by country and age at first use /stats12/tditab108b tditab108b Table-TDI-108-partii.xml
Table TDI tditab108 108 iii New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available New stimulants (other than cocaine) inpatient clients by country and age at first use /stats12/tditab108c tditab108c Table-TDI-108-partiii.xml
Table TDI tditab108 108 iv New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available New hallucinogen inpatient clients by country and age at first use /stats12/tditab108d tditab108d Table-TDI-108-partiv.xml
Table TDI tditab108 108 v New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available New hypnotics and sedatives inpatient clients by country and age at first use /stats12/tditab108e tditab108e Table-TDI-108-partv.xml
Table TDI tditab108 108 vi New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available New volatile inhalant inpatient clients by country and age at first use /stats12/tditab108f tditab108f Table-TDI-108-partvi.xml
Table TDI tditab108 108 vii New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available New cannabis inpatient clients by country and age at first use /stats12/tditab108g tditab108g Table-TDI-108-partvii.xml
Table TDI tditab108 108 viii New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available New 'other drugs' inpatient clients by country and age at first use /stats12/tditab108h tditab108h Table-TDI-108-partviii.xml
Table TDI tditab109 109 i All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available All opioid inpatient clients by country and age at first use /stats12/tditab109a tditab109a Table-TDI-109-parti.xml
Table TDI tditab109 109 ii All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available All cocaine (HCI and 'crack') inpatient clients by country and age at first use /stats12/tditab109b tditab109b Table-TDI-109-partii.xml
Table TDI tditab109 109 iii All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available All stimulants (other than cocaine) inpatient clients by country and age at first use /stats12/tditab109c tditab109c Table-TDI-109-partiii.xml
Table TDI tditab109 109 iv All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available All hallucinogen inpatient clients by country and age at first use /stats12/tditab109d tditab109d Table-TDI-109-partiv.xml
Table TDI tditab109 109 v All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available All hypnotics and sedatives inpatient clients by country and age at first use /stats12/tditab109e tditab109e Table-TDI-109-partv.xml
Table TDI tditab109 109 vi All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available All volatile inhalant inpatient clients by country and age at first use /stats12/tditab109f tditab109f Table-TDI-109-partvi.xml
Table TDI tditab109 109 vii All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available All cannabis inpatient clients by country and age at first use /stats12/tditab109g tditab109g Table-TDI-109-partvii.xml
Table TDI tditab109 109 viii All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available All 'other drugs' inpatient clients by country and by age at first use /stats12/tditab109h tditab109h Table-TDI-109-partviii.xml
Table TDI tditab111 111 i Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available New opioid outpatient clients by country and frequency of use (%) /stats12/tditab111a tditab111a Table-TDI-111-parti.xml
Table TDI tditab111 111 ii Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available All opioid outpatient clients by country and frequency of use (%) /stats12/tditab111b tditab111b Table-TDI-111-partii.xml
Table TDI tditab111 111 iii Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available New cocaine (HCI and ‘crack’) outpatient clients by country and frequency of use (%) /stats12/tditab111c tditab111c Table-TDI-111-partiii.xml
Table TDI tditab111 111 iv Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available All cocaine (HCI and ‘crack’) outpatient clients by country and frequency of use (%) /stats12/tditab111d tditab111d Table-TDI-111-partiv.xml
Table TDI tditab111 111 v Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available New stimulants (other than cocaine) outpatient clients by country and frequency of use (%) /stats12/tditab111e tditab111e Table-TDI-111-partv.xml
Table TDI tditab111 111 vi Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available All stimulants (other than cocaine) outpatient clients by country and frequency of use (%) /stats12/tditab111f tditab111f Table-TDI-111-partvi.xml
Table TDI tditab111 111 vii Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available New cannabis outpatient clients by country and frequency of use (%) /stats12/tditab111g tditab111g Table-TDI-111-partvii.xml
Table TDI tditab111 111 viii Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available All cannabis outpatient clients by country and frequency of use (%) /stats12/tditab111h tditab111h Table-TDI-111-partviii.xml
Table TDI tditab112 112 i Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available New opioid inpatient clients by country and frequency of use (%) /stats12/tditab112a tditab112a Table-TDI-112-parti.xml
Table TDI tditab112 112 ii Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available All opioid inpatient clients by country and frequency of use (%) /stats12/tditab112b tditab112b Table-TDI-112-partii.xml
Table TDI tditab112 112 iii Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available New cannabis inpatient clients by country and frequency of use (%) /stats12/tditab112c tditab112c Table-TDI-112-partiii.xml
Table TDI tditab112 112 iv Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available All cannabis inpatient clients by country and frequency of use (%) /stats12/tditab112d tditab112d Table-TDI-112-partiv.xml
Table TDI tditab112 112 v Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available New stimulants (other than cocaine) inpatient clients by country and frequency of use (%) /stats12/tditab112e tditab112e Table-TDI-112-partv.xml
Table TDI tditab112 112 vi Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available All stimulants (other than cocaine) inpatient clients by country and frequency of use (%) /stats12/tditab112f tditab112f Table-TDI-112-partvi.xml
Table TDI tditab112 112 vii Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available New cocaine (HCI and ‘crack’) inpatient clients by country and frequency of use (%) /stats12/tditab112g tditab112g Table-TDI-112-partvii.xml
Table TDI tditab112 112 viii Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available All cocaine (HCI and ‘crack’) inpatient clients by country and frequency of use (%) /stats12/tditab112h tditab112h Table-TDI-112-partviii.xml
Table TDI tditab113 113   All clients entering treatment for opioids by country and type of opioid misused (%), 2010 or most recent year available   /stats12/tditab113 tditab113 Table-TDI-113-part0.xml
Table TDI tditab114 114   Primary opioids distribution among all clients entering treatment by country and type of treatment centre (%), 2010   /stats12/tditab114 tditab114 Table-TDI-114-part0.xml
Table TDI tditab115 115 i HCL and Crack use of clients entering outpatient treatment , 2010 or most recent year available New outpatient clients by country and type of cocaine product /stats12/tditab115a tditab115a Table-TDI-115-parti.xml
Table TDI tditab115 115 ii HCL and Crack use of clients entering outpatient treatment , 2010 or most recent year available All outpatient clients by country and type of cocaine product /stats12/tditab115b tditab115b Table-TDI-115-partii.xml
Figure TDI tdifig1 1 i Trend in estimated number of new clients entering treatment by selected primary drugs, 2005 to 2010 Percentage by primary drug /stats12/tdifig1a tdifig1a Table-TDI-g01-parti.xml
Figure TDI tdifig1 1 ii Trend in estimated number of new clients entering treatment by primary drug used, from 2005 to 2010 Numbers of clients by primary drug /stats12/tdifig1b tdifig1b Table-TDI-g01-partii.xml
Figure TDI tdifig2 2 i New and all clients entering treatment by primary drug: heroin, cocaine, cannabis, other stimulants and other drugs in 2010. New clients /stats12/tdifig2a tdifig2a Table-TDI-g02-parti.xml
Figure TDI tdifig2 2 ii New and all clients entering treatment by primary drug: heroin, cocaine, cannabis, other stimulants and other drugs in 2010. All clients /stats12/tdifig2b tdifig2b Table-TDI-g02-partii.xml
Figure TDI tdifig3 3 i Trend in estimated number of all clients entering treatment by selected primary drug used, 2005 to 2010 Percentage by primary drug /stats12/tdifig3a tdifig3a Table-TDI-g03-parti.xml
Figure TDI tdifig3 3 ii Trend in estimated number of all clients entering treatment by selected primary drugs, 2005 to 2010 Numbers of clients by primary drug /stats12/tdifig3b tdifig3b Table-TDI-g03-partii.xml
Figure TDI tdifig7 7   New outpatient clients injecting opioid as primary drug from 2005 to 2010 in 18 countries supplying data   /stats12/tdifig7 tdifig7 Table-TDI-g07-part0.xml

About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >>

Contact us

EMCDDA
Praça Europa 1, Cais do Sodré
1249-289 Lisbon
Portugal
Tel. (351) 211 21 02 00
Fax (351) 218 13 17 11

More contact options >>

Page last updated: Monday, 03 December 2012